Results for both the randomized, blinded portion and long-term, open-label portion of the pivotal RNS showed statistically significant reductions in seizure frequency with acceptably low rates of complications. With time, device technology is likely to be refined and improved, both through technical advances and additional clinical data.
DR. KATHERINE NOE and DR. JOSEPH DRAZKOWSKI are epilepsy specialists at the Mayo Clinic, Scottsdale, Ariz. They were both investigators in the RNS trial.
DR. NOE
DR. DRAZKOWSKI